PMID- 37674023
OWN - NLM
STAT- MEDLINE
DCOM- 20240122
LR  - 20240202
IS  - 1530-0447 (Electronic)
IS  - 0031-3998 (Print)
IS  - 0031-3998 (Linking)
VI  - 95
IP  - 1
DP  - 2024 Jan
TI  - Effects of fetal growth restriction on the perinatal neurovascular unit and 
      possible treatment targets.
PG  - 59-69
LID - 10.1038/s41390-023-02805-w [doi]
AB  - The neurovascular unit (NVU) within the brain is a multicellular unit that 
      synergistically acts to maintain blood-brain barrier function and meet cerebral 
      metabolic demand. Recent studies have indicated disruption to the NVU is 
      associated with neuropathology in the perinatal brain. Infants with fetal growth 
      restriction (FGR) are known to be at increased risk of neurodevelopmental 
      conditions including motor, learning, and behavioural deficits. There are 
      currently no neuroprotective treatments for these conditions. In this review, we 
      analyse large animal studies examining the effects of FGR on the perinatal NVU. 
      These studies show altered vascularity in the FGR brain as well as blood-brain 
      barrier dysfunction due to underlying cellular changes, mediated by 
      neuroinflammation. Neuroinflammation is a key mechanism associated with 
      pathological effects in the FGR brain. Hence, targeting inflammation may be key 
      to preserving the multicellular NVU and providing neuroprotection in FGR. A 
      number of maternal and postnatal therapies with anti-inflammatory components have 
      been investigated in FGR animal models examining targets for amelioration of NVU 
      disruption. Each therapy showed promise by uniquely ameliorating the adverse 
      effects of FGR on multiple aspects of the NVU. The successful implementation of a 
      clinically viable neuroprotective treatment has the potential to improve outcomes 
      for neonates affected by FGR. IMPACT: Disruption to the neurovascular unit is 
      associated with neuropathology in fetal growth restriction. Inflammation is a key 
      mechanism associated with neurovascular unit disruption in the growth-restricted 
      brain. Anti-inflammatory treatments ameliorate adverse effects on the 
      neurovascular unit and may provide neuroprotection.
CI  - (c) 2023. The Author(s).
FAU - Wu, Bing Anthony
AU  - Wu BA
AD  - Department of Paediatrics, Monash University, Melbourne, VIC, Australia.
FAU - Chand, Kirat K
AU  - Chand KK
AD  - UQ Centre for Clinical Research, Faculty of Medicine, The University of 
      Queensland, Brisbane, QLD, Australia.
FAU - Bell, Alexander
AU  - Bell A
AD  - Department of Obstetrics and Gynaecology, Monash University, Melbourne, VIC, 
      Australia.
AD  - The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, 
      Australia.
FAU - Miller, Suzanne L
AU  - Miller SL
AD  - Department of Obstetrics and Gynaecology, Monash University, Melbourne, VIC, 
      Australia.
AD  - The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, 
      Australia.
FAU - Colditz, Paul B
AU  - Colditz PB
AD  - UQ Centre for Clinical Research, Faculty of Medicine, The University of 
      Queensland, Brisbane, QLD, Australia.
AD  - Perinatal Research Centre, Royal Brisbane and Women's Hospital, Brisbane, QLD, 
      Australia.
FAU - Malhotra, Atul
AU  - Malhotra A
AD  - Department of Paediatrics, Monash University, Melbourne, VIC, Australia.
AD  - The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, 
      Australia.
AD  - Monash Newborn, Monash Children's Hospital, Melbourne, VIC, Australia.
FAU - Wixey, Julie A
AU  - Wixey JA
AD  - UQ Centre for Clinical Research, Faculty of Medicine, The University of 
      Queensland, Brisbane, QLD, Australia. j.wixey@uq.edu.au.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230906
PL  - United States
TA  - Pediatr Res
JT  - Pediatric research
JID - 0100714
RN  - 0 (Anti-Inflammatory Agents)
SB  - IM
MH  - Pregnancy
MH  - Animals
MH  - Infant, Newborn
MH  - Infant
MH  - Female
MH  - Humans
MH  - *Fetal Growth Retardation
MH  - *Neuroinflammatory Diseases
MH  - Brain/metabolism
MH  - Blood-Brain Barrier
MH  - Anti-Inflammatory Agents/therapeutic use
PMC - PMC10798895
COIS- The authors declare no competing interests.
EDAT- 2023/09/07 00:42
MHDA- 2024/01/22 06:42
PMCR- 2023/09/06
CRDT- 2023/09/06 23:29
PHST- 2023/03/01 00:00 [received]
PHST- 2023/08/16 00:00 [accepted]
PHST- 2023/08/04 00:00 [revised]
PHST- 2024/01/22 06:42 [medline]
PHST- 2023/09/07 00:42 [pubmed]
PHST- 2023/09/06 23:29 [entrez]
PHST- 2023/09/06 00:00 [pmc-release]
AID - 10.1038/s41390-023-02805-w [pii]
AID - 2805 [pii]
AID - 10.1038/s41390-023-02805-w [doi]
PST - ppublish
SO  - Pediatr Res. 2024 Jan;95(1):59-69. doi: 10.1038/s41390-023-02805-w. Epub 2023 Sep 
      6.